Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747463 | 0.91 | EPHX1 (0.46) | NPC1RAB9APOLBEPHX1GAA | |
| SCHEMBL5750876 | 0.86 | ALDH1A1 (0.38) | NPC1RAB9ALMNATP53THRB | |
| SCHEMBL5747448 | 0.85 | NPC1 (0.45) | NPC1RAB9APOLBEPHX1GAA | |
| SCHEMBL5866725 | 0.84 | IMPDH2 (0.45) | GAA | |
| SCHEMBL5748810 | 0.83 | NPC1 (0.50) | NPC1RAB9APOLBEPHX1GAA | |
| SCHEMBL5750018 | 0.82 | POLB (0.47) | NPC1RAB9APOLBEPHX1BRAF | |
| SCHEMBL5750157 | 0.81 | FGFR1 (0.56) | — | |
| SCHEMBL5748453 | 0.81 | FGFR1 (0.56) | — | |
| SCHEMBL5749355 | 0.80 | LMNA (0.49) | NPC1RAB9APOLBEPHX1LMNA | |
| SCHEMBL5750533 | 0.79 | TYK2 (0.53) | NPC1RAB9APOLBEPHX1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048888-A1 | Novel compounds and uses thereof | TEK, TIE1, KDR | NPC1 2798/4885RAB9A 2298/4885POLB 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.